Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg
Launched by MYLAN PHARMACEUTICALS INC · Mar 31, 2008
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • healthy, adult subjects, 18 years and older
- • able to swallow medication
- Exclusion Criteria:
- • institutionalized subjects
- • history of any significant disease
- • use of any prescription or OTC medications within 14 days of start of study
- • received any investigational products within 30 days prior to start of study
About Mylan Pharmaceuticals Inc
Mylan Pharmaceuticals Inc. is a global healthcare company dedicated to providing access to high-quality medicines across a diverse range of therapeutic areas. With a strong emphasis on innovation and affordability, Mylan develops, manufactures, and markets a broad portfolio of generic and specialty pharmaceuticals. Committed to improving patient outcomes, the company actively engages in clinical trials to advance its product offerings and enhance therapeutic options. Mylan's robust research and development efforts are complemented by strategic partnerships and a deep understanding of the healthcare landscape, positioning it as a leader in the pharmaceutical industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Fargo, North Dakota, United States
Patients applied
Trial Officials
James D Carlson, Pharm. D.
Principal Investigator
PRACS Institute Ltd.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials